<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39360294</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2757-8038</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Alpha psychiatry</Title><ISOAbbreviation>Alpha Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project-Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol.</ArticleTitle><Pagination><StartPage>555</StartPage><EndPage>560</EndPage><MedlinePgn>555-560</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5152/alphapsychiatry.2024.241549</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Treatment-resistant depression (TRD) affects around 20-30% of people with major depressive disorder. In 2019, esketamine nasal spray was approved for TRD by both the US Food and Drug Administration and the European Medicines Agency. While its clinical efficacy and safety are proven, the mechanisms underlying its antidepressant effect remain unclear. The use of metabolomics may allow understanding the metabolic effects of esketamine and predicting biological features associated with clinical response in TRD. Nonetheless, there is a lack of studies exploring the predictive value of metabolomics. The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) project aims at identifying metabolic biosignatures that may represent novel correlates of response to esketamine treatment.</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="UNASSIGNED">This is the protocol of an observational, prospective study.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We plan to select 60 people with TRD from 3 clinical sites in Italy. The participants will be administered with esketamine nasal spray, following standard clinical practice, twice a week for 4 weeks ("induction phase"), then once a week for 4 additional weeks ("maintenance phase"). We will test the correlations between baseline metabolic profile and depressive symptom improvement at study endpoints (weeks 4 and 8) and we will explore the likelihood of different metabolic phenotypes between responders and non-responders.</AbstractText><AbstractText Label="EXPECTED RESULTS" NlmCategory="UNASSIGNED">An involvement of energy metabolism, amino acid metabolism, urea cycle, and nitric oxide synthesis in response to treatment with esketamine nasal spray is hypothesized.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Unbiased data from untargeted metabolomics associated with clinical changes after esketamine treatment may contribute to define new paradigms for precision psychiatry-oriented, personalized care of TRD.</AbstractText><CopyrightInformation>2024 authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bartoli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-2612-4119</Identifier><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavaleri</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5342-9394</Identifier><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riboldi</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-8188-800X</Identifier><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crocamo</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2979-2107</Identifier><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Filippis</LastName><ForeName>Renato</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6928-1224</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zandonella Callegher</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0003-5193-6909</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paglia</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4724-6801</Identifier><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-9781-4219</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Fazio</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5375-3565</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr√†</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5375-3565</Identifier><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Alpha Psychiatry</MedlineTA><NlmUniqueID>9918284277106676</NlmUniqueID><ISSNLinking>2757-8038</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">esketamine</Keyword><Keyword MajorTopicYN="N">major depressive disorder</Keyword><Keyword MajorTopicYN="N">metabolomics</Keyword></KeywordList><CoiStatement>Declaration of Interests: Francesco Bartoli is Editor-in-Chief of Alpha Psychiatry and was not involved in the processing of this article. In the last three years, he has received consultant fees by IQVIA Solutions Italy and Edra S.p.A., and carried out paid editorial activities for Elsevier and AVES. In the last three years Renato de Filippis has received speaker fee from Janssen, Angelini, Lundbeck, and Rovi, and travel support from Rovi, Otsuka, Lundbeck, and Janssen. In the last three years Umberto Albert received speaker fee from Angelini Pharma, Janssen Pharmaceutica, OM Pharma Suisse, Lundbeck, Fidia, and Boehringer. The other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39360294</ArticleId><ArticleId IdType="pmc">PMC11443282</ArticleId><ArticleId IdType="doi">10.5152/alphapsychiatry.2024.241549</ArticleId><ArticleId IdType="pii">ap-25-4-555</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rosson S, de Filippis R, Croatto G, et al. Brain stimulation and other biological non-pharmacological interventions in mental disorders: an umbrella review. Neurosci Biobehav Rev. 2022;139:104743. (10.1016/j.neubiorev.2022.104743)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2022.104743</ArticleId><ArticleId IdType="pubmed">35714757</ArticleId></ArticleIdList></Reference><Reference><Citation>Maj M, Stein DJ, Parker G, et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry. 2020;19(3):269 293. (10.1002/wps.20771)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wps.20771</ArticleId><ArticleId IdType="pmc">PMC7491646</ArticleId><ArticleId IdType="pubmed">32931110</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsugiyama LE, Moraes RCM, Moraes YAC, Francis-Oliveira J. Promising new pharmacological targets for depression: the search for efficacy. Drug Discov Today. 2023;28(12):103804. (10.1016/j.drudis.2023.103804)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2023.103804</ArticleId><ArticleId IdType="pubmed">37865307</ArticleId></ArticleIdList></Reference><Reference><Citation>Maina G, Adami M, Ascione G, et al. Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel. Ann Gen Psychiatry. 2023;22(1):48. (10.1186/s12991-023-00478-7)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12991-023-00478-7</ArticleId><ArticleId IdType="pmc">PMC10668442</ArticleId><ArticleId IdType="pubmed">37996836</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre RS, Alsuwaidan M, Baune BT, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394 412. (10.1002/wps.21120)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wps.21120</ArticleId><ArticleId IdType="pmc">PMC10503923</ArticleId><ArticleId IdType="pubmed">37713549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoli F, Wlkinson ST. Ketamine and esketamine for suicidal ideation: recent progress and practical issues. Aust N Z J Psychiatry. 2020;54(2):206 207. (10.1177/0004867419894064)</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0004867419894064</ArticleId><ArticleId IdType="pubmed">31830803</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoli F, Clerici M, Carr√† G. Antidepressant response and dissociative effects after ketamine treatment: two sides of the same coin? J Clin Psychiatry. 2017;78(9):e1318. (10.4088/JCP.17lr11789)</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.17lr11789</ArticleId><ArticleId IdType="pubmed">29345870</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartoli F, Riboldi I, Crocamo C, Di Brita C, Clerici M, Carr√† G. Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. Neurosci Biobehav Rev. 2017;77:232 236. (10.1016/j.neubiorev.2017.03.010)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2017.03.010</ArticleId><ArticleId IdType="pubmed">28342764</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Esketamine is approved in Europe for treating resistant major depressive disorder. BMJ. 2019;367:l7069. (10.1136/bmj.l7069)</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l7069</ArticleId><ArticleId IdType="pubmed">31862692</ArticleId></ArticleIdList></Reference><Reference><Citation>Estrade I, Petit AC, Sylvestre V, et al. Early effects predict trajectories of response to esketamine in treatment-resistant depression. J Affect Disord. 2023;342:166 176. (10.1016/j.jad.2023.09.030)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2023.09.030</ArticleId><ArticleId IdType="pubmed">37738705</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B, MahmoudianDehkordi S, Voort JLV, et al. Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study. Psychiatry Res. 2022;314:114655. (10.1016/j.psychres.2022.114655)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2022.114655</ArticleId><ArticleId IdType="pubmed">35738038</ArticleId></ArticleIdList></Reference><Reference><Citation>Moaddel R, Shardell M, Khadeer M, et al. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Psychopharmacol (Berl). 2018;235(10):3017 3030. (10.1007/s00213-018-4992-7)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-018-4992-7</ArticleId><ArticleId IdType="pmc">PMC6193489</ArticleId><ArticleId IdType="pubmed">30116859</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotroff DM, Corum DG, Motsinger-Reif A, et al. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Transl Psychiatry. 2016;6(9):e894. (10.1038/tp.2016.145)</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2016.145</ArticleId><ArticleId IdType="pmc">PMC5048196</ArticleId><ArticleId IdType="pubmed">27648916</ArticleId></ArticleIdList></Reference><Reference><Citation>Villase√±or A, Ramamoorthy A, Silva dos Santos M, et al. A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. Br J Pharmacol. 2014;171(8):2230 2242. (10.1111/bph.12494)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12494</ArticleId><ArticleId IdType="pmc">PMC3976632</ArticleId><ArticleId IdType="pubmed">24684390</ArticleId></ArticleIdList></Reference><Reference><Citation>Paglia G, Del Greco FM, Sigurdsson BB, et al. Influence of collection tubes during quantitative targeted metabolomics studies in human blood samples. Clin Chim Acta. 2018;486:320 328. (10.1016/j.cca.2018.08.014)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2018.08.014</ArticleId><ArticleId IdType="pubmed">30114408</ArticleId></ArticleIdList></Reference><Reference><Citation>Paglia G, Stocchero M, Cacciatore S, et al. Unbiased metabolomic investigation of Alzheimer‚Äôs disease brain points to dysregulation of mitochondrial aspartate metabolism. J Proteome Res. 2016;15(2):608 618. (10.1021/acs.jproteome.5b01020)</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.5b01020</ArticleId><ArticleId IdType="pmc">PMC5751881</ArticleId><ArticleId IdType="pubmed">26717242</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453 1457. (10.1016/S0140-6736(07)61602-X)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61602-X</ArticleId><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.</Citation></Reference><Reference><Citation>First MB, Williams JBW, Karg RS, Spitzer RL. Structured clinical interview for DSM-5 ‚Äì Research version (SCID-5 for DSM-5, Research version; SCID-5-RV). American Psychiatric Association; 2015.</Citation></Reference><Reference><Citation>Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382 389. (10.1192/bjp.134.4.382)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.134.4.382</ArticleId><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrmann N, Black SE, Lawrence J, Szekely C, Szalai JP. The Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcome. Stroke. 1998;29(3):618 624. (10.1161/01.str.29.3.618)</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.str.29.3.618</ArticleId><ArticleId IdType="pubmed">9506602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. Research: validation of the Massachusetts General Hospital antidepressant treatment history questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322 325. (10.1111/j.1755-5949.2009.00102.x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2009.00102.x</ArticleId><ArticleId IdType="pmc">PMC6493891</ArticleId><ArticleId IdType="pubmed">19769599</ArticleId></ArticleIdList></Reference><Reference><Citation>Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants [published correction appears in Br J Psychiatry. 2010 May;196(5):417]. Br J Psychiatry. 2009;195(3):202 210. (10.1192/bjp.bp.108.061960)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.108.061960</ArticleId><ArticleId IdType="pubmed">19721108</ArticleId></ArticleIdList></Reference><Reference><Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429 435. (10.1192/bjp.133.5.429)</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.133.5.429</ArticleId><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):799 812. (10.2466/pr0.1962.10.3.799)</Citation><ArticleIdList><ArticleId IdType="doi">10.2466/pr0.1962.10.3.799</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, L√∂we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092 1097. (10.1001/archinte.166.10.1092)</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.10.1092</ArticleId><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TK, Niklewski PJ, Martin JF, Obara S, Egan TD. Enhancing a sedation score to include truly noxious stimulation: the Extended Observer‚Äôs Assessment of Alertness and Sedation (EOAA/S). Br J Anaesth. 2015;115(4):569 577. (10.1093/bja/aev306)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aev306</ArticleId><ArticleId IdType="pubmed">26385665</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11(1):125 136. (10.1023/A:1024465317902)</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1024465317902</ArticleId><ArticleId IdType="pubmed">9479681</ArticleId></ArticleIdList></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266 1277. (10.1176/appi.ajp.2011.10111704)</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2011.10111704</ArticleId><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28 37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880930</ArticleId><ArticleId IdType="pubmed">20526405</ArticleId></ArticleIdList></Reference><Reference><Citation>Scalone L, Cortesi PA, Mantovani LG, Ciampichini R, Cesana G. Reference Eq-5d-3l and Eq-5d-5l data from the Italian general population. Value Health. 2014;17(7):A514 A515. (10.1016/j.jval.2014.08.1591)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2014.08.1591</ArticleId><ArticleId IdType="pubmed">27201592</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Arlington: American Psychiatric Association; 2000.</Citation></Reference><Reference><Citation>Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140(6):734 739. (10.1176/ajp.140.6.734)</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ajp.140.6.734</ArticleId><ArticleId IdType="pubmed">6846631</ArticleId></ArticleIdList></Reference><Reference><Citation>D√ºnnwald T, Paglia G, Weiss G, et al. High intensity concentric-eccentric exercise under hypoxia changes the blood metabolome of trained athletes. Front Physiol. 2022;13:904618. (10.3389/fphys.2022.904618)</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2022.904618</ArticleId><ArticleId IdType="pmc">PMC9260056</ArticleId><ArticleId IdType="pubmed">35812339</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57(1):289 300. (10.1111/j.2517-6161.1995.tb02031.x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1995.tb02031.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaleri D, Riboldi I, Crocamo C, Paglia G, Carr√† G, Bartoli F. Evidence from preclinical and clinical metabolomics studies on the antidepressant effects of ketamine and esketamine. Neurosci Lett. 2024;831:137791. (10.1016/j.neulet.2024.137791) [Epub ahead of print].</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2024.137791</ArticleId><ArticleId IdType="pubmed">38670523</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>